A knowledge translation tool improved osteoporosis disease management in primary care: an interrupted time series analysis

Table 2 Results of the interrupted time series analysis for initiation of osteoporosis investigations and treatments, combined across the three sites*

Outcomes	Mean of proportions across the three sites (SD)		% Increase	Pvalue^†
Outcomes	Baseline	Intervention	% Increase	Pvalue^†
Initiation of BMD testing	2.79 (1.27)	6.15 (2.24)	3.4	<0.001
95% CI	1.86 to 3.74	3.38 to 8.42	2.03 to 4.68	<0.001
Initiation of any osteoporosis medication ^‡	0.42 (0.36)	0.87 (0.66)	0.5	0.006
95% CI	0 to 1.13	0 to 2.16	0.15 to 0.85	0.006
Initiation of calcium + vitamin D	0.70 (0.56)	1.58 (0.95)	0.9	<0.001
95% CI	0 to 1.80	0 to 3.44	0.39 to 1.41	<0.001
Initiation of any nutritional supplement (calcium or vitamin D)	0.97 (0.71)	2.13 (1.28)	1.2	0.001
95% CI	0 to 2.36	0 to 4.64	0.49 to 1.91	0.001

*BMD, bone mineral density; SD, standard deviation.
^†From autoregressive integrated moving-average (ARIMA) model. Intercept only model is fitted since the slopes are not significantly different from zero.
^†The following osteoporosis medications were considered: any bisphosphonate (alendronate, etidronate, risedronate, zoledronic acid), any selective estrogen receptor modulator (e.g., raloxifene), nasal calcitonin, parathyroid hormone, and hormone replacement therapy.

ISSN: 1748-5908